Article Versions Notes

Tarantelli C, Gaudio E, Hillmann P, Spriano F, Sartori G, Aresu L, Cascione L, Rageot D, Kwee I, Beaufils F, et al. The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers. 2019; 11(6):775. https://doi.org/10.3390/cancers11060775

Tarantelli, Chiara, Eugenio Gaudio, Petra Hillmann, Filippo Spriano, Giulio Sartori, Luca Aresu, Luciano Cascione, Denise Rageot, Ivo Kwee, Florent Beaufils, and et al. 2019. "The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax" Cancers 11, no. 6: 775. https://doi.org/10.3390/cancers11060775

Tarantelli, C., Gaudio, E., Hillmann, P., Spriano, F., Sartori, G., Aresu, L., Cascione, L., Rageot, D., Kwee, I., Beaufils, F., Zucca, E., Stathis, A., Wymann, M. P., Cmiljanovic, V., Fabbro, D., & Bertoni, F. (2019). The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers, 11(6), 775. https://doi.org/10.3390/cancers11060775